Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Not Applicable

Completed

• Conditions: Recurrent Urinary Tract Infection
• Interventions: Dietary Supplement: Nanotechnology Structured water Magnalife; Dietary Supplement: Ordinary bottled drinking water; Drug: Trimethoprim

• Registration Number: NCT04306731
• Lead Sponsor: University of Sulaimani

Brief Summary

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Detailed Description

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Study Timeline

• Study Start: 2014-09-20
• Primary Completion: 2017-04-21
• Study Completion: 2017-04-21
• Status Verified: 2020-03
• Study First Submitted: 2020-03-11
• Study First Submitted QC: 2020-03-11
• Study First Posted: 2020-03-13
• Last Update Submitted: 2020-03-13
• Last Update Posted: 2020-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 437

Inclusion Criteria

• ≥ 2 (two or more than two) UTI in the last 6 months
• ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion Criteria

• immunotherapy
• radiotherapy
• malignancy
• steroids
• chronic infections
• chemotherapy
• immunosuppressive drugs
• anatomical abnormality of the urinary tract
• surgical operation the urinary tract

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Interventional (Group M)	Nanotechnology Structured water Magnalife	The group of patients given nanotechnology structured water magnalife
Placebo (Group O)	Ordinary bottled drinking water	The group of patients given ordinary bottled drinking water
Control (Group T)	Trimethoprim	The group of patients given Trimethoprim

Primary Outcome Measures

Name	Time	Method
Recurrent Urinary Tract Infection	Twelve months	Urinalysis by GUE (\>10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of ≥105 colony-forming units (CFU) per mL)

Secondary Outcome Measures

Name	Time	Method
Time to first recurrent UTI	Twelve months	The time since the beginning of the study until the first recurrent UTI (days)

Trial Locations

Locations (1)

College of Medicine, University of Sulaimani; 🇮🇶 Sulaymaniyah, Kurdistan Region, Iraq